Tuesday - October 20, 2026
GSK: Jemperli Approved in US as First and Only Immunotherapy for Adults With MSI-H/dMMR Locally Advanced Rectal Cancer
October 20, 2026
LONDON, England, Oct. 20 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:

* * *

19 October 2026

Jemperli (dostarlimab) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

* Approval based on AZUR-1 data showing clinically significant proportion of participants with no detectable signs of cancer one year or more after treatment

* N . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products